Results for Buffers & Concentrates ( 825 )
Preclinical and clinical successes of Adeno-associated virus (AAV)-mediated gene therapy have established AAV as an ideal and safe therapeutic vector. Moreover, these successes have motivated research in both discovering and engineering novel AAV capsids that are more selective and clinically desirable than existing capsids. When injecting AAV particles into animals, it is necessary to use highly purified particles that do not contain any residual AAV host cells. Isolating AAV particles from the AAV host cells is conventionally conducted using freeze-thaw or sonication methods. However, these methods are time consuming and carry significant amounts of proteins from the host cells. The AAV ONE-Extract™ Solution is a reagent for quickly extracting AAV particles from AAV host cells. This reagent provides a simple and efficient method for isolating the AAV particles and is suitable for all AAV serotypes. The resulting viral particles are well-suited for cell infection or further purifica